Share Talk LTD cover art

Share Talk LTD

Share Talk LTD

By: Share Talk LTD
Listen for free

Designed for Private - Retail Investors, bloggers, brokers, PR, listed companies to communicate on one information portal. Please note we are an unregulated website and will never give out advice. We are here to make investing a level playing field.

Economics Personal Finance
Episodes
  • Zak Mir speaks with Orcadian Energy CEO Steve Brown
    Jul 16 2026

    Zak Mir talks to Steve Brown, CEO of Orcadian Energy (AIM: ORCA), as the company announces it has commenced the Assessment Phase for the Earlham and Orwell gas fields, with a preferred development concept involving an offshore power station with carbon capture to fuel a co-located data centre, creating an "Earlham Gigagrid."

    This project aims to monetize the gas resource, estimated at 114 billion cubic feet for Earlham and 31 billion cubic feet for Orwell, by generating approximately 200 MW of low-carbon power for a data centre, with captured carbon dioxide reinjected into the Earlham reservoir.

    The company has also agreed to a deferred repayment schedule for approximately £1.34 million in loans from The Independent Power Corporation Limited, now due by December 31, 2027, with interest fixed at 8.5% per annum.

    Orcadian Begins Assessment Phase for Offshore Gas-to-Data Centre Project

    Orcadian Energy has commenced the Assessment Phase for the development of the Earlham and Orwell gas fields on its 100%-owned licence P2680.

    The company’s preferred development concept is an offshore power station with integrated carbon capture, fuelled by gas from Earlham and Orwell, to supply a co-located offshore data centre. Orcadian said the project could form the first phase of an islanded, low-carbon offshore grid, branded the Earlham Gigagrid.

    The concept is designed to monetise Earlham gas, which has a high carbon dioxide content, by generating power at the field, capturing the carbon dioxide and reinjecting it into the reservoir.

    The company said a power station at Earlham could supply around 200MW of electrical power, or IT load, to an offshore data centre.

    Orcadian and its consultants have conceived a platform complex capable of supporting a 200MW offshore data centre hall and providing the energy for that facility.

    The group is establishing a new company, Earlham Gigagrid Ltd, to incubate the project and enable potential direct investment from third parties.

    Orcadian estimates Earlham contains 114bcf of methane resources, while the previously depleted Orwell field could produce a further 31bcf.

    The company said the proposed scheme could reduce pressure on the national grid while supporting rising demand for compute power driven by artificial intelligence.

    Chief executive Steve Brown said the concept could be transformational for the value of licence P2680 and may ultimately attract interest from hyperscalers and specialist AI cloud infrastructure providers. He added that Orcadian will engage with the NSTA and other relevant regulators as part of the concept select process.

    The project remains subject to NSTA approval, a Letter of No Objection for the selected concept, regulatory consents, commercial agreements and financing.

    Show More Show Less
    13 mins
  • Zak Mir interviews Ajax Resources CEO Ippolito Cattaneo
    Jul 28 2026

    Zak Mir talks to Ippolito Cattaneo, CEO of Ajax Resources, as the natural resources investment company announces it has entered into a binding preliminary agreement to exchange its Puna Metals portfolio, including the Eureka Project, for the Rachaite Prospect and El Salto Project in Argentina, with no immediate cash consideration.

    This strategic move aims to consolidate Ajax’s land position in a prospective copper-silver district, immediately adjoining its flagship Macacha Copper-Silver Project with the El Salto acquisition, and provides an alternative route to acquire the Rachaite polymetallic project.

    The transaction is subject to a 90-day mutual due diligence period and a 120-day exclusivity period, with the final structure to be determined during due diligence.

    Highlights

    · Binding preliminary agreement executed with MMSA in respect of the proposed acquisition of the Rachaite/Chocaya and El Salto mining projects.

    · 90-day mutual due diligence period covering technical, legal, environmental, corporate, financial and commercial matters.

    · 120-day binding exclusivity period, extendable by mutual agreement.

    · El Salto is located immediately adjacent to Ajax’s flagship Macacha Copper-Silver Project and would materially strengthen the Company’s strategic land position, providing the opportunity to evaluate the broader geological potential of the district.

    · Rachaite/Chocaya comprises the Rachaite Prospect and the Mina Chocaya exploration licence in Jujuy Province and has previously been announced by the Company as a highly prospective polymetallic exploration project.

    · The Company is evaluating the optimal transaction structure, including whether the consideration will entail the transfer of the shares of Puna or, alternatively, the transfer of the underlying mining rights comprising the Puna portfolio, with the final structure to be determined during the due diligence process and reflected in the definitive transaction documentation.

    · The Proposed Transaction would provide an alternative mechanism to complete the previously announced acquisition of Rachaite while simultaneously acquiring El Salto.

    · The Proposed Transaction involves no immediate cash consideration, allowing the parties to complete a reciprocal exchange of mining assets while preserving the Company’s capital for exploration, resource definition and project advancement.

    · Completion of the Proposed Transaction remains subject to the satisfactory completion of due diligence, execution of definitive documentation and satisfaction of customary closing conditions.

    Ippolito Ingo Cattaneo, Chief Executive Officer of Ajax Resources Plc, commented:

    “Since acquiring the Eureka Project and the adjoining La Escondida licences for aggregate consideration of US$250,000, Ajax has secured the environmental approvals required to commence exploration, become the first company in the project’s history to drill the property following more than 400 years of historic mining activity, expanded the licence package through the acquisition of the La Escondida 1 and La Escondida 2 exploration licences and commenced the permitting process for a proposed alluvial gold operation. These achievements have materially advanced Eureka and created the opportunity to consider how the value generated by the project can best be redeployed across the Company’s wider portfolio.

    The Proposed Transaction would complete our previously announced acquisition of the Rachaite Prospect while expanding our flagship Macacha Copper-Silver Project through the acquisition of the immediately adjoining El Salto Project. We believe this would create a larger and more strategically coherent exploration position in north-west Argentina, providing the opportunity to evaluate the broader geological potential of the Macacha district.

    The Proposed Transaction involves no immediate cash consideration, preserving the Company’s capital for exploration and project advancement. Our objective is to concentrate exploration expenditure on larger, district-scale opportunities that are more advanced and have greater near-term production potential. We look forward to working with Madero Minerals to complete our due diligence and negotiate the definitive transaction documentation.”

    https://www.share-talk.com/zak-mir-interviews-ajax-resources-ceo-ippolito-cattaneo/

    Show More Show Less
    14 mins
  • Zak Mir Speaks to MedPal AI CEO Jason Drummond
    Aug 4 2026
    Zak Mir talks to Jason Drummond, CEO of Medpal (AIM: MPAL), as the AI-native digital health and pharmacy group provided a trading update for July 2026, the first month in which the Group's three revenue streams (NHS prescriptions, private prescriptions and SaaS software subscriptions) have all been in operation.Medpal has moved from zero dispensing revenue in October 2025 to an annualised run rate of approximately £8.6 million, based on July 2026 performance. That growth has been achieved in just nine months, with all three revenue streams now operating together: NHS prescriptions, private prescriptions and SaaS software subscriptions.The opportunity is substantial, but the strategy is not simply about selling weight-loss medication. It is about building the underlying health operating system that connects prescribing, automated dispensing, delivery, medicine administration and AI-led patient support.From Zero to £8.6 Million Run RateOur dispensing operations began from a standing start in October 2025. By 1 June 2026, the annualised revenue run rate had passed £5 million. By July, it had reached around £8.6 million across NHS and private dispensing.That momentum is particularly encouraging because the business has been built with minimal marketing expenditure. Until recently, investment was directed primarily towards the infrastructure needed to operate safely and at scale.Prescription dispensing is not a simple e-commerce exercise. Prescribing, dispensing and fulfilment have to be done properly, with robust processes, appropriate technology and serious operational capacity behind them.Investing Early in Scalable Pharmacy InfrastructureMedpal has invested heavily in two large warehouse facilities designed to process more than 300,000 prescription orders per month. The operations are supported by robotic dispensing technology, providing 24-hour capacity and 99.9% dispensing accuracy.The key advantage of automation is operating leverage. Once the dispensing infrastructure is in place, volumes can rise without costs increasing at the same rate. That creates the potential for substantial growth from the existing platform rather than requiring a matching expansion in overhead for every new prescription.In July, the business processed nearly 50,000 NHS orders. At the same time, private patients are now coming through the New Health service at new.co.uk.The heavy lifting on facilities, automation and technology has largely been completed. The focus can now move towards filling that capacity, growing the patient base and building recurring revenue.Why Medpal’s Revenue Can CompoundOne of the most important features of the model is that revenue is designed to repeat. This is not a business that starts each month from zero. NHS prescriptions are generally linked to long-term prescribing plans and recurring monthly dispensing. Private treatment plans also create monthly patient relationships and repeat requirements. MRX software subscriptions provide an additional recurring SaaS revenue stream. Each month begins with the previous month’s revenue base already in place. New patients, prescriptions and subscriptions then build on top of that foundation. This is why growth can become increasingly meaningful as the platform scales.The July 2026 trading update marked the first month in which all three revenue streams were operational together. That matters because NHS dispensing, private dispensing and software subscriptions each contribute to a broader and more resilient commercial model.Building a Health Operating System, Not Just a PharmacyAcquisitions may play a role in the future, but the core strategy has always been to build an integrated health operating system.The aim is to connect every important stage of the medication journey through a single platform:PrescribingRobotic dispensingDeliveryMedicine administration at the bedside for care home residentsAI-driven patient support through Juno AI That fully connected platform did not already exist as something that could simply be bought. It had to be assembled and built.Previous smaller acquisitions have therefore been strategic assembly acquisitions. They supplied elements needed for the wider platform, including robotic dispensing capabilities. The objective was not acquisition for its own sake. It was to create the infrastructure required to operate a genuinely integrated digital health and pharmacy business.There may be opportunities to acquire additional assets in future, but the immediate priority is to use the platform already built, invest in marketing and grow a significant operating business.GLP-1 Medication Is a Major Private Healthcare OpportunityThe launch of New Health at new.co.uk brings Medpal into the rapidly growing GLP-1 market, including medicines such as Wegovy and Mounjaro.The UK market is already significant. An estimated 2 million people are using GLP-1 medicines in the UK, generating around £300 million of revenue per month. This...
    Show More Show Less
    6 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet